Ghassan Abou-Alfa, MD, MBA

Abou-Alfa GK et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Gastrointestinal Cancers Symposium 2022;Abstract 379.

Finn RS et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Gastrointestinal Cancers Symposium 2021;Abstract 267.

Kelley RK et al. Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial. ESMO 2021;Abstract VP10-2021.

Tanios Bekaii-Saab, MD

Bekaii-Saab TS et al. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol 2021;32(9):1111-26. Abstract

Meric-Bernstam F et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study. Gastrointestinal Cancers Symposium 2021;Abstract 299.

Oh D-Y et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. ASCO GI 2022;Abstract 378.

Richard S Finn, MD

El-Khoueiry AB et al. Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. Gastrointestinal Cancers Symposium 2021;Abstract 269.

Finn RS et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2. Gastrointestinal Cancers Symposium 2022;Abstract 423.

Llovet JM et al. Hepatocellular carcinoma. Nat Rev Primers 2021;7(1):6. Abstract

Qin S et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. Gastrointestinal Cancers Symposium 2022;Abstract 383.

Robin K (Katie) Kelley, MD

Israel MA et al. Comparative genomic analysis of intrahepatic cholangiocarcinoma: Biopsy type, ancestry, and testing patterns. Oncologist 2021;26(9):787-96. Abstract

Javle M et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 2021;6(10):803-15. Abstract

Lamarca A et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021;22(5):690-701. Abstract

Zhu AX et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021;7(11):1669-77. Abstract